La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Alembic Pharmaceuticals Croissance future
Future contrôle des critères 3/6
Alembic Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 18.7% et de 10.6% par an respectivement. Le BPA devrait croître de de 17.9% par an. Le rendement des capitaux propres devrait être 15.6% dans 3 ans.
Informations clés
18.7%
Taux de croissance des bénéfices
17.9%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 17.6% |
Taux de croissance des recettes | 10.6% |
Rendement futur des capitaux propres | 15.6% |
Couverture par les analystes | Good |
Dernière mise à jour | 13 Aug 2024 |
Mises à jour récentes de la croissance future
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Recent updates
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
3/31/2027 | 84,576 | 10,874 | 8,944 | N/A | 4 |
3/31/2026 | 76,276 | 8,526 | 6,800 | N/A | 12 |
3/31/2025 | 68,355 | 6,842 | 5,281 | N/A | 12 |
6/30/2024 | 63,042 | 6,299 | N/A | N/A | N/A |
3/31/2024 | 62,286 | 6,158 | 4,757 | 8,032 | N/A |
12/31/2023 | 61,181 | 5,902 | N/A | N/A | N/A |
9/30/2023 | 59,966 | 5,317 | 2,042 | 6,027 | N/A |
6/30/2023 | 58,766 | 5,285 | N/A | N/A | N/A |
3/31/2023 | 56,526 | 3,420 | 2,805 | 7,240 | N/A |
12/31/2022 | 56,619 | 2,113 | N/A | N/A | N/A |
9/30/2022 | 54,246 | 2,662 | 2,893 | 6,751 | N/A |
6/30/2022 | 52,419 | 3,153 | N/A | N/A | N/A |
3/31/2022 | 53,058 | 5,209 | 1,267 | 5,524 | N/A |
12/31/2021 | 51,704 | 7,609 | N/A | N/A | N/A |
9/30/2021 | 52,131 | 8,771 | 1,767 | 8,309 | N/A |
6/30/2021 | 53,778 | 10,412 | N/A | N/A | N/A |
3/31/2021 | 53,931 | 11,465 | 8,039 | 14,634 | N/A |
12/31/2020 | 53,196 | 11,521 | N/A | N/A | N/A |
9/30/2020 | 52,144 | 10,937 | 6,209 | 12,378 | N/A |
6/30/2020 | 49,982 | 10,066 | N/A | N/A | N/A |
3/31/2020 | 46,058 | 8,288 | -2,858 | 4,491 | N/A |
12/31/2019 | 43,259 | 7,282 | N/A | N/A | N/A |
9/30/2019 | 41,349 | 6,638 | 482 | 7,967 | N/A |
6/30/2019 | 40,211 | 6,176 | N/A | N/A | N/A |
3/31/2019 | 39,347 | 5,844 | 476 | 8,120 | N/A |
12/31/2018 | 38,604 | 5,542 | N/A | N/A | N/A |
9/30/2018 | 36,823 | 5,149 | N/A | N/A | N/A |
6/30/2018 | 33,445 | 4,364 | N/A | N/A | N/A |
3/31/2018 | 31,302 | 4,126 | N/A | 3,124 | N/A |
12/31/2017 | 29,894 | 4,119 | N/A | N/A | N/A |
9/30/2017 | 29,264 | 3,678 | N/A | N/A | N/A |
6/30/2017 | 30,165 | 3,661 | N/A | N/A | N/A |
3/31/2017 | 31,052 | 4,032 | N/A | 3,286 | N/A |
12/31/2016 | 30,130 | 3,999 | N/A | N/A | N/A |
9/30/2016 | 31,584 | 5,828 | N/A | N/A | N/A |
6/30/2016 | 32,942 | 7,515 | N/A | N/A | N/A |
3/31/2016 | 31,232 | 7,200 | N/A | 9,477 | N/A |
12/31/2015 | 30,185 | 6,986 | N/A | N/A | N/A |
9/30/2015 | 26,086 | 4,998 | N/A | N/A | N/A |
6/30/2015 | 21,469 | 2,881 | N/A | N/A | N/A |
3/31/2015 | 20,579 | 2,829 | N/A | 1,718 | N/A |
12/31/2014 | 20,167 | 2,739 | N/A | N/A | N/A |
9/30/2014 | 19,906 | 2,692 | N/A | N/A | N/A |
6/30/2014 | 19,303 | 2,535 | N/A | N/A | N/A |
3/31/2014 | 18,642 | 2,355 | N/A | 2,400 | N/A |
12/31/2013 | 17,770 | 2,179 | N/A | N/A | N/A |
9/30/2013 | 16,610 | 2,002 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de APLLTD ( 18.7% par an) est supérieure au taux d'épargne ( 6.7% ).
Bénéfices vs marché: Les bénéfices de APLLTD ( 18.7% par an) devraient croître plus rapidement que le marché Indian ( 16.9% par an).
Croissance élevée des bénéfices: Les bénéfices de APLLTD devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de APLLTD ( 10.6% par an) devrait croître plus rapidement que le marché Indian ( 10% par an).
Croissance élevée des revenus: Le chiffre d'affaires de APLLTD ( 10.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de APLLTD devrait être faible dans 3 ans ( 15.6 %).